0RAD Stock Overview
A clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
OSE Immunotherapeutics SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €8.52 |
| 52 Week High | €9.00 |
| 52 Week Low | €3.25 |
| Beta | 0.90 |
| 11 Month Change | 4.41% |
| 3 Month Change | 29.09% |
| 1 Year Change | 99.99% |
| 33 Year Change | -20.08% |
| 5 Year Change | n/a |
| Change since IPO | 42.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RAD | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 4.3% | 1.5% | -0.3% |
| 1Y | 100.0% | -15.9% | 9.8% |
Return vs Industry: 0RAD exceeded the UK Biotechs industry which returned -15.9% over the past year.
Return vs Market: 0RAD exceeded the UK Market which returned 9.8% over the past year.
Price Volatility
| 0RAD volatility | |
|---|---|
| 0RAD Average Weekly Movement | 10.7% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0RAD's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0RAD's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 52 | Nicolas Poirier | www.ose-immuno.com |
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren’s Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation; CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a novel bispecific checkpoint inhibitor platform that targets PD-1 to fight primary and secondary resistance mechanisms developed by cancers.
OSE Immunotherapeutics SA Fundamentals Summary
| 0RAD fundamental statistics | |
|---|---|
| Market cap | €188.82m |
| Earnings (TTM) | €46.03m |
| Revenue (TTM) | €69.92m |
4.1x
P/E Ratio2.7x
P/S RatioIs 0RAD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RAD income statement (TTM) | |
|---|---|
| Revenue | €69.92m |
| Cost of Revenue | €0 |
| Gross Profit | €69.92m |
| Other Expenses | €23.88m |
| Earnings | €46.03m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.12 |
| Gross Margin | 100.00% |
| Net Profit Margin | 65.84% |
| Debt/Equity Ratio | 49.6% |
How did 0RAD perform over the long term?
See historical performance and comparison